Sirupulladi ennai for Upper Respiratory Tract Infection.

Clinical evaluation of sirupulladi ennai(a siddha drug) for the treatment of Neerkanamantham(URI) in children.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/05/008641

Enrollment

Registered

2017-05-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patient with symptoms cough running nose fever headache

Interventions

Intervention1: Sirupulladi ennai: 1.6 ml BD after food 3 days oral route Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Cough, Running nose, Fever and Headache

Exclusion criteria

Exclusion criteria: children below 3 years and above 7 years of age continuous fever for 5 or more days signs of moderate and severe dehydration H/o childhood asthma patients with any other serious illness

Design outcomes

Primary

Measure	Time frame
Reduction in the cough will be assessed by modified LCQ questionnaire reduction in headaches and associated symptoms assessed by clinicallyTimepoint: 3 days	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr P Arulmozhi

National institute of siddha

mmssiddha@rediffmail.com9940266442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026